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Abstract
Introduction: Primary effusion lymphoma is a recently recognized entity of AIDS related non-Hodgkin lymphomas.
Despite Africa being greatly affected by the HIV/AIDS pandemic, an extensive MEDLINE/PubMed search failed to
find any report of primary effusion lymphoma in sub-Saharan Africa. To our knowledge this is the first report of
primary effusion lymphoma in sub-Saharan Africa. We report the clinical, cytomorphologic and
immunohistochemical findings of a patient with primary effusion lymphoma.
Case presentation: A 70-year-old newly diagnosed HIV-positive Ugandan African woman presented with a three-
month history of cough, fever, weight loss and drenching night sweats. Three weeks prior to admission she
developed right sided chest pain and difficulty in breathing. On examination she had bilateral pleural effusions.
Haematoxylin and eosin stained cytologic sections of the formalin-fixed paraffin-embedded cell block made from
the pleural fluid were processed in the Department of Pathology, Makerere University, College of Health Sciences,
Kampala, Uganda. Immunohistochemistry was done at the Institute of Haematology and Oncology “L and A
Seragnoli”, Bologna University School of Medicine, Bologna, Italy, using alkaline phosphatase anti-alkaline
phosphatase method. In situ hybridization was used for detection of Epstein-Barr virus.
The tumor cells were CD45+, CD30+, CD38+, HHV-8 LANA-1+; but were negative for CD3-, CD20-, CD19-, and
CD79a- and EBV RNA+ on in situ hybridization. CD138 and Ki-67 were not evaluable. Our patient tested HIV
positive and her CD4 cell count was 127/μL.
Conclusions: A definitive diagnosis of primary effusion lymphoma rests on finding a proliferation of large
immunoblastic, plasmacytoid and anaplastic cells; HHV-8 in the tumor cells, an immunophenotype that is CD45
+, pan B-cell marker negative and lymphocyte activated marker positive. It is essential for clinicians and
pathologists to have a high index of suspicion of primary effusion lymphoma when handling HIV positive
patients who have effusions without palpable tumor masses. Basic immunohistochemistry is essential for
definitive diagnosis.
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P r i m a r ye f f u s i o nl y m p h o m a( P E L )i sar a r ea g g r e s s i v e
B-cell lymphoma which was first identified in 1989 as a
subset of body-cavity-based lymphomas [1,2]. It
accounts for only 0.13% of all AIDS related malignancies
among AIDS patients in the USA [3]. The WHO classi-
fication recognizes it as a unique entity of non-Hodgkin
lymphoma (NHL) [2].
It has been suggested that Kaposi sarcoma herpes
virus/Human herpes virus-8 (KSHV/HHV-8) is the cau-
sative agent of PEL. In Europe and America very high
seroprevalences of HHV-8 (around 67%) have been
reported among HIV-positive men who have sex with
men [4]. It was initially thought that the transmission in
Western countries was sexual [5], however, a recent
study in Texas showed high HHV-8 seroprevalences of
26% among children, indicating another mode of trans-
mission of HHV-8 [6].
In Africa, studies have shown considerable variation in
the seroprevalence rates of HHV-8 infection among
adults and children; the highest adult rates of 26-100%
have been found in Uganda, Cameroon, Ivory Coast,
Gambia, the Democratic Republic of Congo, Tanzania,
Zambia and South Africa.
Nigeria, Ghana, Zimbabwe and Egypt have prevalence
rates of 50% and the countries with relatively low rates
of 25% and below are the Central African Republic, Eri-
trea and Senegal [7].
A recent study revealed increasing seroprevalence of
HHV-8 with age among Ugandan children, from 10%
among two-year-olds to 36.4% in eight-year-olds, in
contrast to South African children where there were ser-
oprevalence rates of 7.5-9% [8].
In East and Central Africa, the HHV-8 seroprevalence
reaches 80% in the adult population. In Uganda, HHV-8
seroprevalence is approximately 40% in adulthood and
studies have also confirmed transmission by blood
transfusion [9,10].
In sub-Saharan Africa, there have been very few reports
of PEL and this is probably because effusions are often
not made into cell blocks, and even when they are, no
immunohistochemistry is performed [11,12]. Hence, it is
possible that PEL is being missed as an important sub-
type of AIDS-related NHL [13]. Despite HIV, Epstein-
Barr virus (EBV) and HHV-8 being endemic in Uganda,
no case of PEL has, before now, been reported from the
country. We report a case of PEL in a 70-year-old HIV-
infected woman from Kampala, Uganda.
Case presentation
A 70-year-old newly diagnosed HIV-positive Ugandan
African woman presented with a three-month history of
cough, fever, weight loss and drenching night sweats.
Three weeks prior to admission she developed right
sided chest pain and difficulty in breathing. There was
no history of haemoptysis or bleeding from any site. She
had occasional palpitations. There was no history of leg
swelling, orthopnea or paroxysmal nocturnal dyspnoea.
She had been vomiting for two days prior to admission,
but had no oral sores or alteration in bowel habits.
A review of the rest of her systems was unremarkable.
This was her first admission to hospital; she reported
having been unwell for three months and had received
treatment for cough from a nearby clinic. As she was
newly diagnosed with HIV, she had not yet received cotri-
moxazole or highly active antiretroviral therapy (HAART).
She was nulliparous, had never married but had had sev-
eral sexual partners. She had been smoking a pipe (with
tobacco); however, she denied alcohol consumption.
On examination, she was elderly, sick looking, with
severe pallor, dehydration and wasting. She had no lym-
phadenopathy, jaundice, or edema. Her liver, spleen and
kidneys were not palpable. She had no Kaposi sarcoma
lesions on her skin or mucus membranes. She had
tachycardia (92 beats per minute) with apparently nor-
mal heart sounds but she had a functional systolic mur-
mur. Her blood pressure was 125/90 mmHg. She had
tachypnoea (35 breaths per minute), reduced air entry
and fine crackles on the right side of her chest.
Results of laboratory investigations are shown in
table 1. A chest x-ray showed bilateral pleural effusions
and subcutaneous emphysema. Echocardiography
showed a mild pericardial effusion.
On ultrasonography, her liver, spleen, kidney and pan-
creas were normal in size, shape and echo pattern. Her
urinary bladder wall was normal. There was no ascites
or lymphadenopathy. Bilateral large pleural effusions
were confirmed. No solid tumor masses were present.
Table 1 Results of laboratory investigations
Laboratory test Result Normal range
Serum creatinine 172 μmol/L 44-106 μmol/L
Alanine aminotransferase 8.8 I Units/L 0-41 I Units/L
Serum calcium 2.0 mmol/L 2.2-2.6 mmol/L
Potassium 6.3 mmol/L 3.5-5.5 mmol/L
Sodium 151.2 mmol/L 135-150 mmol/L
WBC (total) 8.5 × 10





Platelets 219 × 10
3/μL 150-400 × 10
3/μL
Haemoglobin 6.8 g/Dl 12-18 g/dL
CD4 cell count 127/μL 410-1590/μL
CD8 cell count 1178/μL 190-1140/μL
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from her right hemithorax and sent to the Department
of Pathology, Makerere University, College of Health
Sciences, Kampala, Uganda, where it was cytocentri-
fuged. The sediment was made into a cell block and
haematoxylin and eosin stained slides revealed a neo-
plastic proliferation of large lymphoid cells with round
to irregular nuclei, prominent nucleoli, and varying
amounts of vacuolated cytoplasm. There were immuno-
blastic, plasmablastic and anaplastic variants with
bizarre, pleomorphic nuclei (Figure 1A). They included
multinucleated and Reed-Sternberg-like cells. From
these findings a preliminary diagnosis of PEL was made.
Since immunohistochemistry is not routinely available
in Uganda, it was carried out at the Institute of Haema-
tology and Oncology “L and A Seragnoli”, Bologna
University School of Medicine, Bologna, Italy. The alka-
line phosphatase anti-alkaline phosphatase method and
the primary antibodies listed in table 2 were used. In
situ hybridization was also used for detection of EBV.
The tumor cells were CD45+ (Figure 1C), CD30+,
CD38+, HHV-8 LANA-1+ (Figure 1D); but were nega-
tive for CD3-, CD20- (Figure 1B), CD19-, and CD79a-
and EBV RNA+ (Figure 1C inset) on in situ hybridiza-
tion. CD138 and Ki-67 were not evaluable. These find-
ings confirmed the diagnosis of PEL. The patient tested
HIV-positive and her CD4 cell count was 127/μL.
Treatment: She was initially rehydrated with normal
saline and 5% dextrose, and later received a blood trans-
fusion. She also received allopurinol, ceftriaxone and
metronidazole. After she had stabilized, she was given




2 and Oncovin (vincristine) 14 mg/m
2 on
day one and prednisolone 100 mg on days one to five,
repeated every 21 days). In addition, she received ome-
prazole, metoclopramide and dexamethasone. She regis-
tered some improvement after the first course of
chemotherapy and was allowed home. She was dis-
charged through the Infectious Disease Institute clinic
to be initiated on HAART. She was due to return for
subsequent anti-cancer treatment but died two days
after discharge from our hospital.
Discussion
We have reported the case of a patient who presented
with all the features of PEL that have been described
elsewhere [14,15]. This was the first AIDS defining ill-
ness in this patient even though she had very low CD4
counts.
The strong positivity for HHV-8 in this patient is
similar to what other authors have found in studies on
HIV-positive PEL patients [14,16]. HHV-8, by defini-
tion, has to be present in the tumor cells in order to
make a diagnosis of PEL [15]. The co-infection of
HHV-8 and EBV in this patient is interesting. Both
HHV-8 and EBV are g-herpes viruses and are closely
related. While evidence of HHV-8 is essential for diag-
nosis of PEL, the role of HHV-8 in the pathogenesis is
not clear. However, we know that EBV immortalizes
B-cells while HHV-8 seems not to. It would, therefore,
appear that HHV-8 by itself is not sufficient for the
development of PEL. It seems that EBV causes
unchecked proliferation of B-cells leading to develop-
ment of PEL and, according to Fan and others, “once
PELs have developed HHV-8 appears to be the driving
force [14].” Recently, several cases of EBV negative
PEL have been reported implying that HHV-8 plays a
critical role in pathogenesis [17].
About 31 cases of HHV-8 independent PEL (HHV-8-
unrelated PEL-like lymphoma) have been reported in
Figure 1 At light microscopy, the sample consisted of a frankly
neoplastic population provided with plasmablastic and/or
anaplastic morphology (Figure 1A), which turned out CD3-,
CD20- (Figure 1B), CD79a-, CD45+ (Figure 1C), CD38+, CD30+,
IRF4+, LANA-1+ (Figure 1D), EBER+ (Figure 1C inset), and Ki-
67>90%. Based on these findings, we made a diagnosis of PEL.
Table 2 Primary antibodies used for diagnosis
Antibody Clone Source Antigen retrieval Dilution
CD45 LCA Dako EDTA 750 W 1:100
CD3 SP7 Immunotech EDTA 750 W 1:250
CD20 L26 Dako EDTA 750 W 1:200
CD30 Ber- H2 Prof. B Falini* EDTA 900 W 1:3
CD38 SPC32 Novocastra EDTA 750 W 1:10
CD79a JCB117 Prof. D Mason
§ EDTA 750 W 1:10
HHV8 13B10 Menarini EDTA 750 W 1:10
CD138 - Neomarkers EDTA 900 W 1:20
Ki-67 Mib-1 Dako EDTA 900 W 1:20
*Kindly provided by Prof. Brunangelo Falini, Perugia University, Perugia, Italy.
§Kindly provided by Prof. David Y Mason, Oxford University, Oxford, UK.
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more precisely as HHV-8-unrelated large B-cell lympho-
mas because of the differences observed in its pathogen-
esis, morphology and immunophenotype (it expresses a
B-cell phenotype unlike PEL), and is associated with
hepatitis C virus infection in 30-40% of cases [19]. The
clinical behavior and prognosis are significantly different
from that of PEL patients. The HHV-8-unrelated large
B - c e l ll y m p h o m ap a t i e n t st e n dt oh a v em o r ei n d o l e n t
disease that has been observed to resolve spontaneously
and, when treated, these patients have a much better
prognosis than the HIV-positive, HHV-8 positive PEL
patients - who have a very poor outcome [19]. This
therefore proves that the two are separate entities.
PEL, possibly uniquely, presents as serous effusions in
the pleural, peritoneal and pericardial cavity without
identifiable tumor masses or lymphadenopathy.
The morphological presentation is as a large B-cell
neoplasm and the tumor cells contain KSHV/HHV-8
DNA and lack c-myc translocations. PEL most com-
m o n l ya f f e c t sm a l eA I D Sp a t i e n t sa n dw a sf i r s tr e c o g -
nized in men who have sex with men [20,21]. However,
a few cases have been reported in women. It is easily
distinguished from other lymphomas because of its unu-
sual morphology with large immunoblastic, plasmacy-
toid and/or anaplastic cells.
The immunophenotypical presentation of PEL cells is
typically as a “null” lymphocyte phenotype, meaning
that CD45 is expressed, but routine B-cell (including
surface and cytoplasmic immunoglobulin, CD19, CD20,
CD79a) and T-cell (CD3, CD4, CD8) markers are
absent. Instead, various markers of lymphocyte activa-
tion (CD30, CD38, CD71, human leukocyte antigen DR)
and plasma cell differentiation (CD138) are usually dis-
played [22].
PELs are of B-cell origin because they have clonal
immunoglobulin gene rearrangements [17,23].
Although immunohistochemical services are not routi-
nely available in Uganda and other resource constrained
countries, it is still possible to suspect PEL with avail-
able clinical and cytomorphologic criteria. These include
lymphomatous effusions limited to the body cavities
with no solid tumor or lymphadenopathy and pleo-
morphic large cells with immunoblastic, plasmacytoid
and anaplastic variants [20].
Regarding PEL, no optimal treatment has yet been
identified [24]. Most HIV-positive PEL patients receive
anthracycline-based multiagent chemotherapy (CHOP;
cyclophosphamide, doxorubicin, vincristine, and predni-
sone) and antiretroviral therapy. Patients with HHV-8
negative large B-cell lymphomas have been shown to
b e n e f i tf r o mi m m u n o t h e r a p ywith rituximab since they
display B-cell immunophenotype, pleurodesis and thora-
cocentesis [25]. However, in resource poor settings such
as Uganda only CHOP and antiretroviral agents are
used [18]. NF-kappa B plays a significant role in PEL
oncogenesis. Studies using new drug regimens directed
against NF-kappa B have shown positive results. These
drugs are currently being developed for therapeutic use
[26,27].
Conclusions
Since a definitive diagnosis of PEL rests on the presence
of HHV-8 in the tumor cells, a lymphoproliferation of
large immunoblastic, plasmacytoid and/or anaplastic
cells, an immunophenotype of leucocyte common anti-
gen CD45 positive, pan B-cell marker negative, and lym-
phocyte activated marker (CD 138, CD30, CD38, human
leukocyte antigen DR and CD71) positive, it is essential
for clinicians and pathologists to develop a high index
of suspicion of PEL when handling HIV-positive patients
with effusions without palpable tumor masses. Basic
immunohistochemistry to confirm the diagnosis is
necessary.
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